AXSM Axsome Therapeutics, Inc.
AXSM Axsome Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-08-17 1 neutral converging
POC $185.06 · VWAP $184.09 · +17.5% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
AXSM Price Structure
Loading timeframes…
Peers
Every watchlist AXSM belongs to, members best 30-day change first — AXSM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
COVERAGE GAP — print not explicitly confirmed in tonight's pulls. The same-day analyst tape is consistent with a report having landed: TD Cowen raised its target to $300 from $275 (Buy), RBC nudged to $304 from $302, Mizuho trimmed to $306 from $310, and BMO initiated at Outperform — plus Axsome initiated the FOCUS-2 Phase 3 pediatric trial of solriamfetol (...
full note →Against street estimates
How AXSM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about AXSM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 7 days ago · Aug 11
- Axsome Therapeutics price target lowered to $306 from $310 at Mizuho
- Axsome Therapeutics initiated with an Outperform at BMO Capital
- Axsome Therapeutics price target raised to $304 from $302 at RBC Capital
- Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
- Axsome Therapeutics price target raised to $300 from $275 at TD Cowen
AXSM research tape
18 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.